Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1000 • ACR Convergence 2020
Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women
Kazuki Yoshida¹, Jiaqi Wang², Susan Malspeis³, Bing Lu⁴, Lauren C. Prisco³, Lily Martin³, Julia Ford², Karen Costenbader⁵, Elizabeth Karlson² and Jeffrey Sparks⁶, ¹Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Personal cigarette smoking has been strongly associated with the risk for developing seropositive RA. Previous studies concerning passive smoking conflict; some suggested that childhood…
Abstract Number: 1016 • ACR Convergence 2020
Annual Cardiac or Orthopedic Procedure Volume in Gout versus Rheumatoid Arthritis: A National Time-trends Study
Jasvinder Singh¹ and John Cleveland¹, ¹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The hospitalization rate for gout has been increasing in recent years with a reduction in people with RA. To our knowledge, there are no…
Abstract Number: 1187 • ACR Convergence 2020
Red Cell Distribution Width Is Associated with ASCVD Risk Score and CVD in RA After Initiation of Methotrexate
Ibtissam Gad¹, Sofi Damjanovska², Lenche Kostadinova³, Alyssa Lange⁴, Christopher Burant⁴, Brigid Wilson⁵, Taissa Bej⁵, Nora Singer⁶, Maya Mattar⁷, David Zidar⁸ and Donald Anthony⁹, ¹Case Western Reserve/ Cleveland VA Medical Center, Cleveland Heights, OH, ²Case Western Reserve University/Cleveland VA Medical Center, Cleveland Heights, OH, ³(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ⁴Case Western Reserve University, Cleveland, ⁵Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁶The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁷Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ⁸Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁹Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Rheumatoid arthritis (RA) has been shown to be associated with increased risk of cardiovascular disease (CVD) and mortality. Red cell distribution width (RDW) represents…
Abstract Number: 1203 • ACR Convergence 2020
Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
Jürgen Wollenhaupt¹, Jacques Morel², Claire Daien³, Adeline Ruyssen-Witrand⁴, Cédric Lukas³, Christophe Richez⁵, Andrea Shapiro⁶, Douglass S Chapman⁷, Magali Cros⁸, Jose L Rivas⁹ and Gustavo Citera¹⁰, ¹Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³CHU Montpellier and University of Montpellier, Montpellier, France, ⁴Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁵Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France, ⁶Pfizer Inc, Peapack, NJ, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Paris, France, ⁹Pfizer SLU, Madrid, Spain, ¹⁰Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: A prior post hoc analysis of tofacitinib clinical trial data reported improvements in RA outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless…
Abstract Number: 1219 • ACR Convergence 2020
Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
Piero Ruscitti¹, Onorina Berardicurti¹, Paola Cipriani¹ and Roberto Giacomelli¹, ¹University of L'Aquila, L'Aquila, Italy
Background/Purpose: The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets by using biologic DMARDs designed for rheumatoid arthritis (RA), and IL-1…
Abstract Number: 1237 • ACR Convergence 2020
Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials
Anthony Sebba¹, Jian Han² and Shalini V. Mohan², ¹Arthritis Associates, Palm Harbor, Tampa, FL, ²Genentech, South San Francisco, CA
Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
Abstract Number: 1462 • ACR Convergence 2020
Intensity and Duration of Silica Exposure Increase Rheumatoid Arthritis Risk Among Coal Miners
Laura Trupin¹, Gabriela Schmajuk², Edward Yelin¹ and Paul Blanc¹, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, Atherton, CA
Background/Purpose: Exposure to inhaled mineral dust, particularly silica, has been associated with increased risk of rheumatoid arthritis and other autoimmune diseases. Coal mining, which can…
Abstract Number: 1537 • ACR Convergence 2020
Usefulness of Ultrasound Assessment of Sarcopenia in Patients with Rheumatoid Arthritis
Takeshi Yoshida¹ and Yoshitaka Kumon¹, ¹Chikamori Hospital, Kochi, Japan
Background/Purpose: Sarcopenia, the age-related loss of muscle mass and function, is associated with numerous risk factors, including rheumatoid arthritis (RA). Although standard diagnostic tool for…
Abstract Number: 1600 • ACR Convergence 2020
Relationship Between Electronic Health Record Vendor and Performance on Patient-reported Outcome Quality Measures in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam¹, Gabriela Schmajuk², Jing Li³, Michael Evans¹, Julia Kay¹ and Jinoos Yazdany³, ¹UCSF, San Francisco, CA, ²University of California, San Francisco, Atherton, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Routine collection of disease activity and patient reported outcomes (PROs) such as functional status assessment in rheumatoid arthritis (RA) are nationally endorsed quality measures…
Abstract Number: 1722 • ACR Convergence 2020
Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire
Laurette van Boheemen¹, Marieke ter Wee², Marie Falahee³, Marian van Beers⁴, Axel Finckh⁵, Aase Hensvold⁶, Karim Raza⁷ and Dirkjan van Schaardenburg⁸, ¹Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, ²Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, ³Sandwell and West Birmingham Hospitals NHS Trust, Birminham, United Kingdom, ⁴Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ⁵Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ⁶Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁷Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁸Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: Accurate prediction of rheumatoid arthritis (RA) development in persons at risk can help to select individuals for early intervention trials. At-risk individuals exhibit a…
Abstract Number: 1738 • ACR Convergence 2020
Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Jing Yang¹, Rong Mu², Chun Li³, Bin Wu⁴, Hongzhi Wang⁵, Wenqiang Fan⁶, Jinmei Zou⁷, Yu Zhang¹, Fen Li⁸, Xiaofeng Rong⁹, Jianhong Wu¹⁰, Yong Wang¹¹, Shengguang Li¹², Yi Zhao¹³, Xiaoqiang Hou¹⁴, Hui Xiao¹⁵, Yuhua Jia¹⁶, Bing Wu¹⁶, Miaomiao Song¹⁶, Fei Xiao¹⁶ and Zhanguo Li¹⁷, ¹Department of Rheumatology, Mianyang Central Hospital, Mianyang, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³People's Hospital, Beijing University Medical School, beijing, China (People's Republic), ⁴Chongqing Hospital of Traditional Chinese Medicine, chongqing, China (People's Republic), ⁵The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ⁶Central Hospital of XinXiang, Xinxiang, China (People's Republic), ⁷Department of Rheumatology, Mianyang Central Hospital, Mianyang, Sichuan, China (People's Republic), ⁸The Second Xiangya Hospital of Central South University, hunan, China (People's Republic), ⁹The First Affiliated Hospital of Chongqing Medical University, chongqing, China (People's Republic), ¹⁰Department of Rheumatology, Dazhou Central Hospital, Dazhou, China (People's Republic), ¹¹The first Hospital Affiliated to AMU (Southernwest Hospital), chongqing, China (People's Republic), ¹²Peking University International Hospital, Beijing, China (People's Republic), ¹³Xuanwu Hospital, Capital Medical University, Beijing, China, Beijing, China (People's Republic), ¹⁴Yichang Central People's Hospital, Beijing, China (People's Republic), ¹⁵Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹⁶Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁷Peking University People’s Hospital, Xicheng, Beijing, China (People's Republic)
Background/Purpose: Treat-to-Target (T2T) strategy are critical for the treatment of RA, but Chinese rheumatologists can hardly provide patients with a complete assessment in the clinic…
Abstract Number: 1756 • ACR Convergence 2020
Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis
Felipe Julio Ramirez Garcia¹, Jose Inciarte-Mundo², Andrea Cuervo³, Raquel Celis⁴, Virginia Ruiz-Esquide⁴, Raul Castellanos-Moreira⁵, Andres Ponce⁴, Jose Gómez-Puerta⁶, Raimon Sanmartí⁶ and Juan Cañete⁷, ¹Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, ²Hospital Universitari Clínic de Barcelona, Barcelona, ³Hospital Clínic, Barcelona, Spain, ⁴Hospital Clinic, Barcelona, Spain, ⁵Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, ⁷Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain and IDIBAPS, Barcelona, Spain
Background/Purpose: To compare long-term clinical and radiographic outcomes among five sets of remission criteria [four clinical and one Ultrasound (US)-based] in a cohort of RA…
Abstract Number: 1957 • ACR Convergence 2020
A Single Cell Stromal Atlas Identifies Conserved Fibroblast Phenotypes Expanded in the Inflamed Synovium, Lung, Intestine, and Salivary Gland
Ilya Korsunsky¹, Kevin Wei², Mathilde Pohin³, Edy Kim⁴, Jason Turner⁵, Saba Nayar⁶, Benjamin Fisher⁷, Karim Raza⁸, Matthias Friedrich⁹, Jennifer Marshall⁵, Adam Croft⁵, Mark Coles¹⁰, Andreas Frei¹¹, Andrew Filer¹², Francesca Barone⁵, Kara Lassen¹¹, Fiona Powrie¹⁰, Christopher Buckley¹³, Michael Brenner² and Soumya Raychaudhuri¹⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, Oxford, United Kingdom, ⁴Brigham and Women’s Hospital, Division of Pulmonary and Critical Care Medicine, Boston, MA, ⁵Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁶Institute for Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁷University Hospitals Birmingham NHS Foundation Trust-Birmingham, Birmingham, United Kingdom, ⁸Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁹Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹⁰Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ¹¹Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology (I2O) Discovery and Translational Area, Roche Innovation Center Basel, Basel, Switzerland, ¹²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ¹³University of Birmingham, Birmingham, United Kingdom, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Pro-inflammatory fibroblasts have been independently implicated in the pathogenesis of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), interstitial lung disease (ILD), and Sjogren’s syndrome…
Abstract Number: 1999 • ACR Convergence 2020
Hydroxychloroquine Is Not Cardiotoxic in Patients with Rheumatoid Arthritis
Jose Felix Restrepo¹, Agustin Escalante¹, Daniel Battafarano², Carlos Lorenzo³ and Inmaculada Del Rincon¹, ¹University of Texas Health Science Center at San Antonio/ Department of Medicine/ Rheumatology, San Antonio, TX, ²San Antonio Military Medical Center, San Antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Hydroxychloroquine (HCQ) has been proposed as a potential treatment for COVID-19, but early reports suggested that it could have cardiotoxic effects. Despite widespread and…
Abstract Number: 2046 • ACR Convergence 2020
Alterations in Circulating CD4+ T Cell Phenotypes in CCP+ Early RA and CCP+ At-risk Individuals by Mass Cytometry
Ye Cao¹, Joshua Keegan², Alessandra Zaccardelli², Gregory Keras³, Jennifer Seifert⁴, Elizabeth Bemis⁵, Marie Feser⁶, M Kristen Demoruelle⁷, Kevin D. Deane⁸, Jill Norris⁵, Michael Brenner⁹, James Lederer¹⁰, V Michael Holers⁶, Jeffrey Sparks¹¹ and Deepak Rao², ¹Brigham and Women’s Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women’s Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ⁵Department of Epidemiology, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁶Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁷University of Colorado, Denver, CO, ⁸2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹⁰BWH Harvard Medical School, Boston, MA, ¹¹Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The cyclic citrullinated peptide (CCP) autoantibody is a highly specific and predictive marker for the clinical diagnosis of RA. Elevation in CCP titers can be…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].